Portal de Periódicos da CAPES

CA 12-5 bei Karzinomen des Verdauungstraktes: Ein Vergleich mit CA 19-9 und CEA bei Karzinomen des Pankreas und Kolon

2008; Thieme Medical Publishers (Germany); Volume: 109; Issue: 51/52 Linguagem: Inglês

10.1055/s-2008-1069483

1439-4413

Rüdiger Klapdor, U. Klapdor, M Bahlo, M. Dallek, B. Kremer, H. van Ackeren, Helmut Schreiber, H. Greten,

Digestive system and related health

In 42 control subjects and 134 patients with benign or malignant disease of the pancreas or large intestine, the recently produced tumour-associated antigen CA 12-5 was determined together with CEA and CA 19-9. Only 4% of controls and patients with benign disease (except those with acute pancreatitis) had CA 12-5 values above 35 U/ml, compared with 60% of patients with pancreas carcinoma and 21% with colon carcinoma. For the former (pancreas carcinoma) there was also a good correlation to stage of tumour (0 of 6 tumours stage TxN0M0, 7 of 11 TxN1M0, 16 of 20 TxN1M1 greater than 35 U/ml) and progression of the malignancy. Simultaneous determination of all three antigens increased the rate of tumour-marker positive patients from 87% (CA 19-9) to 92% for pancreas carcinoma and from 25% (CEA) to 51% for colon carcinoma.